Dernières nouvelles pour BMW (OTC:BMWKY) Stock

BMW is a premium passenger car and motorcycle original equipment manufacturer, home to the brands BMW, Mini Cooper, Rolls-Royce, and BMW Motorrad. BMW sold 2.8 million vehicles in 2023 (2.6 million being passenger cars). In terms of sales volumes, Asia and Europe are BMW's largest regions, contributing 39% and 38%, respectively. BMW's core competence is in the "affordable" luxury channel, with limited exposure to high-end priced vehicles.

BAYERISCHE MTRNWRK U/ADR by Bayerische Motoren Werke AG

Bayerische Motoren Werke AG

Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) has outperformed the market over the past 5 years by 11.67% on an annualized basis producing an average annual return of 24.49%. Currently, Freeport-McMoRan has a market capitalization of $55.61 billion. 
Buying $1000 In FCX: If an investor had bought $1000 of FCX stock 5 years ago, it would be worth $2,976.08 today based on a price of $38.70 for FCX at the time of writing.
<h3>Freeport-McMoRan's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736205307_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Dana White served as the matchmaker who wanted to make a<a href="https://www.benzinga.com/general/sports-betting/23/08/33606870/musk-vs-zuckerberg-billionaire-bout-latest-odds-reveal-clear-favorite-potential-100-bet-wi"> cage fight between billionaires</a> Elon Musk and Mark Zuckerberg a reality. While the fight didn't happen, White has now turned to helping one of the billionaires as a member of his company&#8217;s board of directors.
What Happened: White once said a cage fight between Musk and Zuckerberg could<a href="https://www.benzinga.com/news/23/06/32988611/elon-musk-vs-mark-zuckerberg-fight-back-on-mom-says-no-but-dana-white-says-lets-make-it-happen"> raise millions of dollars</a> for charity.
"This would be the biggest fight ever in the history of the world. It would break all pay-per-view records," White previously said.
While the fight never happened, White is now tasked with helping Zuckerberg's company as he was named a member of the Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) board of directors on Monday.
White, who is the CEO of the UFC said he makes "fights that people want to see." Now alongside his everyday job, White will help Meta usher in the new era of artificial intelligence.
"I've never been interested in joining a board of directors until I got the offer to join Meta's board. I am a huge believer that social media and AI are the future," White said.
White said he's excited to learn more about Meta from the inside and to join the incredible team.
"There is nothing I love more than building brands, and I look forward to helping take Meta to the next level."
The appointment of White brings a Donald Trump ally closer to the social media executive and could create synergies between UFC and Meta. While Trump and Zuckerberg <a href="https://www.benzinga.com/news/24/12/42454227/months-after-trump-threatened-to-put-mark-zuckerberg-in-prison-meta-ceo-donates-1m-to-president-elects-inaugural-event">previously clashed</a> over social media bans imposed on the former president, Zuckerberg recently met with Trump and <a href="https://www.benzinga.com/news/24/12/42454227/months-after-trump-threatened-to-put-mark-zuckerberg-in-prison-meta-ceo-donates-1m-to-president-elects-inaugural-event">donated to his inauguration fund.</a>
The announcement of White joining the Meta board comes on the same day that WWE, which like UFC is owned by TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), is set to make its live debut on streaming giant Netflix.
You may not be a billionaire like Mark Zuckerberg, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/25/01/42798998/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Other Board Appointees: Alongside White, two other Meta board of directors appointees were announced Monday.
Exor CEO John Elkann and investor Charlie Songhurst were also announced as new Meta board members.
Exor, which is controlled by the Agnelli family, is one of the largest European investment companies, according to the press release. Elkann is the executive chairman of both Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) and Ferrari NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>). Exor owns stakes in Stellantis, Ferrari, CNH, Phillips, Louboutin and Juventus Football Club.
"I look forward to bringing my global experience and long-term perspective to the board as Meta continues to shape and push the next frontiers of innovation and technology," Elkann said.
Songhurst is an investor specializing in the technology sector and startups. He previously worked at Microsoft helping with partnerships and M&amp;A.
"As part of Meta's advisory group, I've seen firsthand the opportunities to scale new products and grow AI and enterprise capabilities," Songhurst said.
Zuckerberg highlighted the AI opportunity in Monday's announcement.
"Dana, John and Charlie will add a depth of expertise and perspective that will help us tackle the massive opportunities ahead with AI, wearables and the future of human connection," Zuckerberg said.
META Price Action: Meta stock closed Monday up 4.23% to $630.20 versus a 52-week trading range of $352.05 to $638.40. Meta shares were up 0.66% to $634.35 in after-hours trading. The stock is up 76% over the past year.
TKO shares traded higher on news of the announcement in the after-hours trading market before returning to the $141.63 level it closed at Monday at the time of writing.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/01/42771258/worlds-top-10-richest-people-gained-more-wealth-in-2024-than-costco-and-nikes-combined-valuation-how-elon-musk-warren-buffett-and-others-fared">World&#8217;s Top 10 Richest People Gained More Wealth In 2024 Than Costco And Nike&#8217;s Combined Valuation: How Elon Musk, Warren Buffett And Others Fared</a></li>
</ul>
Photo: Shutterstock

Social Media

Management

After-Hours Center

Tech

RACE

STLA

Dana White Wanted Elon Musk, Mark Zuckerberg In Cage Fight, Now He's On Meta's Board Of Directors

Motorola Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) has outperformed the market over the past 10 years by 10.28% on an annualized basis producing an average annual return of 21.69%. Currently, Motorola Solns has a market capitalization of $76.28 billion. 
Buying $100 In MSI: If an investor had bought $100 of MSI stock 10 years ago, it would be worth $709.32 today based on a price of $456.45 for MSI at the time of writing.
<h3>Motorola Solns's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736204408_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on January 7, 2025 under the ticker symbol "ZYBT."

IPOs

Zhengye Biotechnology Reports Pricing Of Its IPO Of 1.50M Ordinary Shares At $4.00 Per Ordinary Share

CEPO

Cantor Equity Partners I, Inc. Prices Its IPO Of 20M Class A Ordinary Shares At $10.00 Per Share

Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) has outperformed the market over the past 15 years by 1.85% on an annualized basis producing an average annual return of 13.53%. Currently, Valero Energy has a market capitalization of $38.66 billion. 
Buying $100 In VLO: If an investor had bought $100 of VLO stock 15 years ago, it would be worth $659.75 today based on a price of $122.13 for VLO at the time of writing.
<h3>Valero Energy's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736203509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2.46 million shares of common stock. The warrants will have an exercise price of $0.90 per share, will be exercisable upon issuance and expire five years following the date of issuance. The closing of the offering is expected to occur on or about January 7, 2025, subject to the satisfaction of customary closing conditions.

Offerings

ACXP

Acurx Pharmaceuticals Reveals Purchase And Sale Of An Aggregate Of 2.46M Shares Of Its Common Stock At $1.015 Per Share

As a result, the Company closed a total of 1,636 homes in the fourth quarter, including the bulk sale of 103 leased, single-family homes in November 2024, and a total of 6,131 homes for the full year 2024.

LGIH

LGI Homes Reports Closings Of 580 Homes In December 2024

KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) has outperformed the market over the past 5 years by 6.08% on an annualized basis producing an average annual return of 18.9%. Currently, KULR Tech Gr has a market capitalization of $839.87 million. 
Buying $100 In KULR: If an investor had bought $100 of KULR stock 5 years ago, it would be worth $237.67 today based on a price of $3.51 for KULR at the time of writing.
<h3>KULR Tech Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736202621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KULR

Here's How Much $100 Invested In KULR Tech Gr 5 Years Ago Would Be Worth Today

Enovix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) shares are rising in extended trading Monday after the company announced the completion of site acceptance testing for its <a href="https://www.benzinga.com/pressreleases/25/01/g42831392/enovix-completes-site-acceptance-testing-sat-of-fab2">Fab2 in Malaysia</a>.
What Happened: Enovix said it completed&nbsp;site acceptance testing for its high-volume manufacturing line at Fab2&nbsp;in late December. The battery manufacturing company plans to begin mass production later this year.
The site acceptance testing validates the readiness of the company&#8217;s manufacturing equipment and marks the final stage of factory acceptance testing before commercial-scale production begins. Enovix noted the milestone shows Fab2 is fully equipped to produce high-performance silicon batteries at volume.
&#8220;The completion of SAT represents a turning point for Fab2 and for Enovix,&#8221; said Raj Talluri, CEO of Enovix.
&#8220;It reflects the dedication of our team and our commitment to operational excellence. With significant customer interest in our cutting-edge technology, Fab2 will enable us to meet large-scale production demands while maintaining the highest quality standards.&#8221;
See Also: <a href="https://www.benzinga.com/25/01/42762224/bev-market-share-will-increase-across-us-china-europe-in-2025-says-sp-global-mobility">Battery Electric Vehicle Sales To Surge 30%, Capture 17% of Global Light Vehicle Market By 2025: Report</a>
<h1 class="wp-block-heading">Is ENVX A Good Stock To Buy?</h1>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages — such as <a href="https://www.benzinga.com/quote/ENVX">Enovix</a>&#8216;s page, for example — there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Enovix does not pay a dividend, but has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/ENVX">Enovix</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
ENVX Price Action:&nbsp;<a href="http://benzinga.com/quote/envx" target="_blank" rel="noreferrer noopener">Enovix shares</a>&nbsp;were up 5.54% in after-hours, trading at $13.15 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Piotr Swat via Shutterstock

Global

Movers

ENVX

Enovix Shares Are Moving Higher After The Bell: What's Going On?

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.41% on an annualized basis producing an average annual return of 12.85%. Currently, Gilead Sciences has a market capitalization of $113.70 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,101.15 today based on a price of $91.23 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736201708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GILD

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

A Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) analyst sees upcoming revamped and new vehicle models helping to boost sales along with Full Self-Driving licensing potential, brushing aside the company's recent<a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on"> fourth-quarter delivery miss.</a>
The Tesla Analyst: Tesla analyst Stephen Gengaro reiterated a Buy rating on Tesla. He also raised the price target from $441 to $492.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/10/41501607/tesla-q3-earnings-highlights-eps-beat-revenue-miss-shares-climb-on-2025-timeline-for-lower-cost-evs">Tesla Q3 Earnings Highlights: EPS Beat, Revenue Miss, Shares Climb On 2025 Timeline For Lower-Cost EVs</a>
The Analyst Takeaways: The upcoming rollout of the "Model 2" from Tesla is a catalyst, Gengaro said in a new investor note.
Strong demand is anticipated for the lower-priced Model 2, according to the analyst. The introduction of this new vehicle could serve as a new way for Tesla vehicles to be more accessible to a wider range of consumers.
The analyst also highlighted the company's revamped Model 3 and a Model Y refresh as items that could boost vehicle sales, as <a href="https://in.investing.com/news/analyst-ratings/stifel-lifts-tesla-stock-target-buy-rating-on-growth-outlook-93CH-4598738">reported </a>by Investing.com.
"We believe Tesla is very well positioned to deliver robust multi-year growth in 2025-27+," Gengaro said in the note, as <a href="https://x.com/SawyerMerritt/status/1876294513138012509">shared </a>by Sawyer Merritt.
The analyst considers the potential removal of $7,500 in electric vehicle tax credits under the new White House administration as an advantage for Tesla over competitors.
Outside of vehicle sales, the analyst also highlights Tesla's Full Self-Driving and artificial intelligence initiatives that could bring value and revenue to the company and its shares.
"We also believe Tesla's AI-based Full Self-Driving initiative has the potential to generate significant value through both sales of FSD, possible licensing agreements, and a critical part of longer-term Cybercab initiatives."
The analyst's price target increase comes after the delivery miss and the company posting its first annual sales decline on a year-over-year basis. Analysts <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42777950/teslas-first-sales-drop-splits-wall-street-2025-will-be-the-prove-it-year">continue to debate</a> what the short-term and long-term looks like for the electric vehicle leader with new vehicles, robotaxis and FSD among the most covered topics.
Tesla will report fourth-quarter financial results after the market closes on Jan. 29. 
Price Action: Tesla stock was up 0.2% to $411.05 on Monday versus a 52-week trading range of $138.80 to $488.54. Tesla stock is up 71% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42772702/tesla-analyst-says-fsd-test-drive-shows-imperfections-not-ready-for-prime-time-yet">Tesla Analyst Says FSD Test Drive Shows Imperfections, &#8216;Not Ready For Prime Time Yet&#8217;</a></li>
</ul>
Image via Tesla

Analyst Color

Price Target

Reiteration

Analyst Ratings

TSLA

Tesla Stock 'Well Positioned To Deliver Robust Multi-Year Growth': Why Analyst Is Raising Price Target After Deliveries Miss

New York City&#8217;s congestion toll program launched on Sunday, adding new fees for drivers and rideshare customers. Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and LYFT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) lobbied in favor of congestion tolls and are positioned to benefit<a href="https://www.benzinga.com/news/global/25/01/42806918/new-york-citys-historic-congestion-pricing-starts-sunday-uber-and-lyft-passengers-to-pay-for-entering-manhattan"> from the new fees. </a>
What To Know: The new congestion toll program is intended to reduce traffic congestion, improve air quality and raise funds for the city's mass transit system. Most drivers entering Manhattan&#8217;s Congestion Relief Zone, south of 60th Street, will be charged a $9 toll during peak hours while rideshare services will be charged significantly less $1.50 per vehicle. 
Read Next: <a href="https://www.benzinga.com/25/01/42821300/biden-set-to-ban-future-offshore-oil-drilling-4-stocks-to-watch">Biden Set To Ban Future Offshore Oil Drilling: 4 Stocks, 2 ETFs To Watch</a>
According to <a href="https://nypost.com/2025/01/04/us-news/uber-lyft-spent-millions-pushing-for-nyc-congestion-pricing-and-stand-to-make-killing/">a report </a>from the New York Post, Uber and Lyft have spent millions of dollars lobbying in favor of the congestion toll program and stand to benefit from its rollout.
According to the New York Post report, Lyft contributed $18,500 in each of the last four years to Gov. Kathy Hochul's campaign, which championed the new congestion tolls. The Post also reported that Uber spent $2 million between 2015 and 2019 to promote congestion tolls. 
Why It Matters: Uber and Lyft are passing the additional fee to the customer so the increased tolls will not directly affect the companies' bottom lines. The companies could also benefit from reduced traffic leading to faster service and from drivers switching to ridesharing services in order to avoid higher tolls.&nbsp;
Lyft announced it is refunding the new $1.50 congestion fee in the form of a credit for future trips for all rides completed in the month of January.&nbsp;
"Since 2019 rideshare riders have already paid a $2.75 congestion fee to the MTA for rides that start, end or pass through a separate congestion zone that begins below 96th Street in Manhattan. We don't think riders should be double taxed, and we lobbied hard for them to be exempt from this new additional $1.50 congestion fee," the company said in <a href="https://www.lyft.com/blog/posts/navigating-the-new-nyc-congestion-fee-with-lyft">a statement</a> released last week.&nbsp;
Josh Gold, a Uber spokesman, told the New York Post that the company was "early supporters of congestion pricing" but "government can't continue to raise prices and fees on New Yorkers and expect no consequences."
The full impact of congestion tolling on the rideshare services will become clearer as future ridership figures come in.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/42768507/china-slaps-export-restrictions-on-dozens-of-us-companies-boeing-lockheed-martin-general-dynamics-raytheon-affected">China&#8217;s Export Crackdown Hits Boeing, Lockheed Martin And More&nbsp;</a></li>
</ul>
Photo: Shutterstock

Travel

Legal

General

LYFT

UBER

Uber, Lyft Could Gain From New York City Congestion Pricing They Championed

AerCap Prices Offering Of Senior Notes, Consisting Of $750M Of 4.875% Senior Notes Due 2028 And $750 Million Of ' 5.375% Senior Notes Due 2031

Every January, traders and market enthusiasts look to the first month's performance as a potential crystal ball <a href="https://www.benzinga.com/analyst-ratings/analyst-color">for the year ahead. </a>
The &#8216;January Barometer&#8217; and the &#8216;January Effect&#8217;—two staples of market lore—suggest that January holds predictive power over the entire year's stock market trajectory. 
But while these ideas are catchy, investors may find more reliable gains by focusing elsewhere.
<h3 class="wp-block-heading">The January Effect And Barometer: A Closer Look</h3>
The January Effect refers to a historical trend where stocks tend to rise during the month of January. This phenomenon is often attributed to year-end tax-loss harvesting, where investors sell off losing positions in December to offset capital gains, only to reinvest at the start of the new year.
Meanwhile, the January Barometer, introduced by Yale Hirsch in 1972, takes a broader perspective. It suggests that the S&amp;P 500's performance in January can serve as a predictor for the rest of the year. 
The logic behind the January Barometer is simple, with the sentence "as goes January, so goes the year," frequently cited in financial circles. 
According to Ed Yardeni, president of Yardeni Research, the January Barometer has proven accurate more often than not.
Data shows that between 1965 and 2024, January's performance matched the market's full-year direction in 42 out of 59 years, or about 71% of the time. 
Moreover, January ranks as the fourth-best performing month for stocks historically, with an average gain of 1.2% since 1928.
Looking at a more recent history, in 2024, the S&amp;P 500, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), posted a 1.6% gain in January and ended the year up by a strong 23.3%. In 2023, a spectacular 6.3% surge in January set the stage for a 24.4% annual rally, while in 2022, a sharp 6.3% drop in January foreshadowed a nearly 20% decline for the year.
On paper, these stats make January look significant. But are they truly actionable?
<h3 class="wp-block-heading">Flaws In January's Predictive Power</h3>
While intriguing, the January Barometer and Effect often rely on loose correlations rather than causal relationships.
Almost all months of the year, with the sole exclusion of September, tend to show historical gains simply because stock prices have a natural upward trend over time. 
The January Effect, tied to tax-loss selling and reinvestment, also presents logical inconsistencies, as Yardeni highlighted.
If tax-loss selling depresses December's performance, how does December maintain its reputation for the so-called Santa Claus rallies? In fact, December outperforms January historically, with an average gain of 1.3% since 1928, making it the third-best month for stocks.
These contradictions highlight why traders should be cautious when relying on January-based strategies. Statistical quirks don't necessarily translate into consistent profits.
<h3 class="wp-block-heading">Look Beyond January</h3>
January's allure as a market bellwether often overshadows its true significance. Although the January Barometer and Effect have historical appeal, their predictive power is more coincidence than strategy.
&#8220;It is better simply to stay invested for the long run than to trade these two January statistical regularities,&#8221; Yardeni said.
While the January Barometer and Effect have historical merit, their predictive power pales in comparison to the benefits of long-term, fundamentals-based strategies. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42825901/this-key-bond-market-gauge-predicted-major-wall-street-crashes-is-50-drop-looming-in-2025">This Key Bond Market Gauge Predicted Major Wall Street Crashes: Is 50% Drop Looming In 2025?</a></li>
</ul>
Image created by Tara Anand for Investopedia

Broad U.S. Equity ETFs

Psychology

ETFs

'As Goes January, So Goes The Year' - Here's Why Investors Should Focus Elsewhere

Across the recent three months, 22 analysts have shared their insights on Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">13</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $32.45, a high estimate of $40.00, and a low estimate of $25.00. This current average has increased by 7.66% from the previous average price target of $30.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200844_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Confluent's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Confluent. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Confluent compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Confluent's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Confluent's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CFLT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Confluent analyst ratings.</a>
<h2>About Confluent</h2>
Confluent Inc is a new category of data infrastructure designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. Its products include Confluent Platform; Connectors; ksqlDB and others. The company generates revenue from the sale of subscriptions and services. Geographically, it derives a majority of its revenue from the United States. The company provides solutions to Financial Services; Insurance; Retail and eCommerce; Automotive; Government and other sectors.
<h3>A Deep Dive into Confluent's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Confluent's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 24.99%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Confluent's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -29.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Confluent's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.2%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Confluent's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Confluent's debt-to-equity ratio stands notably higher than the industry average, reaching 1.19. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CFLT

What Analysts Are Saying About Confluent Stock

Ratings for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by a high estimate of $82.00 and a low estimate of $58.00. This current average has decreased by 0.93% from the previous average price target of $68.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200837_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of CVS Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CVS Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CVS Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CVS Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CVS Health analyst ratings.</a>
<h2>About CVS Health</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>Breaking Down CVS Health's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.31% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CVS Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CVS Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): CVS Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: CVS Health's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down CVS Health: 14 Analysts Share Their Views

10 analysts have expressed a variety of opinions on Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $175.3, a high estimate of $185.00, and a low estimate of $165.00. This current average has increased by 9.26% from the previous average price target of $160.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200831_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Quest Diagnostics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$182.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$168.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Quest Diagnostics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Quest Diagnostics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Quest Diagnostics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DGX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Quest Diagnostics analyst ratings.</a>
<h2>Get to Know Quest Diagnostics Better</h2>
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
<h3>Quest Diagnostics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Quest Diagnostics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 8.41%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Quest Diagnostics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.35%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Quest Diagnostics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: Quest Diagnostics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.02.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Quest Diagnostics's Future

The Company intends to use the net proceeds from the offering for [general corporate purposes, capital expenditures, working capital and general and administrative expenses].
 &nbsp;

AMST

Amesite Intends To Offer And Sell Shares Of Its Common Stock (Or Pre-funded Warrants In Lieu Thereof) In Public Offering

13 analysts have shared their evaluations of Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $118.08, along with a high estimate of $136.00 and a low estimate of $100.00. This current average has increased by 1.46% from the previous average price target of $116.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200823_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Arch Capital Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$106.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Jay Cohen</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$136.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$104.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jay Cohen</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$126.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$107.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arch Capital Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Arch Capital Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Arch Capital Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACGL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arch Capital Group analyst ratings.</a>
<h2>Discovering Arch Capital Group: A Closer Look</h2>
Arch Capital Group Ltd is a Bermuda company which writes insurance and reinsurance with operations in Bermuda, the United States, Canada, Europe, Australia and United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage two operating segments: corporate and other. The insurance segment provides specialty risk solutions to client across a variety of industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
<h3>Arch Capital Group's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Arch Capital Group displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 36.05%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.83%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Arch Capital Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.74% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Arch Capital Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Arch Capital Group's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

BMW

Actualités

Dernières nouvelles pour BMW (OTC:BMWKY) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL